berinert 500 iu injektio/infuusiokuiva-aine ja liuotin, liuosta varten
csl behring gmbh - c1-esteraasin estäjä - injektio/infuusiokuiva-aine ja liuotin, liuosta varten - 500 iu - proteiini-c1-estäjät
triesence 40 mg/ml injektioneste, suspensio
novartis finland oy - triamcinolone acetonide - injektioneste, suspensio - 40 mg/ml - triamsinoloni
berinert 1500 iu injektiokuiva-aine ja liuotin, liuosta varten
csl behring gmbh - c1-esteraasin estäjä - injektiokuiva-aine ja liuotin, liuosta varten - 1500 iu - proteiini-c1-estäjät
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
vantobra
pari pharma gmbh - tobramysiini - cystic fibrosis; respiratory tract infections - systeemiset bakteerilääkkeet, , aminoglykosidi bakteerilääkkeet - vantobra on tarkoitettu pseudomonas aeruginosan aiheuttaman kroonisen keuhkotulehduksen hoitoon 6-vuotiailla ja sitä vanhemmilla potilailla, joilla on kystinen fibroosi (cf). on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.
theofol 6.6 mg/ml oraaliliuos
takeda oy takeda oy - theophyllinum monohydricum - oraaliliuos - 6.6 mg/ml - teofylliini
librax 5 mg / 2,5 mg tabletti, päällystetty
viatris oy - clidinium bromide, chlordiazepoxide - tabletti, päällystetty - 5 mg / 2,5 mg - klidiini ja psyykenlääke
catapresan 150 mikrog tabletti
glenwood gmbh pharmazeutische erzeugnisse - clonidine hydrochloride - tabletti - 150 mikrog - klonidiini
catapresan 150 mikrog/ml injektioneste, liuos
glenwood gmbh pharmazeutische erzeugnisse - clonidine hydrochloride - injektioneste, liuos - 150 mikrog/ml - klonidiini